GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Upadacitinib extended-release tablets (Rinvoq, selected adult indications)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Rinvoq / upadacitinib ER

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Upadacitinib extended-release tablets (Rinvoq, selected adult indications) - selected U.S. label sections

Product / population
Adult RINVOQ ER tablets for atopic dermatitis, ulcerative colitis or Crohn disease only. Not RINVOQ LQ, pediatric regimens, or other rheumatologic indications.
Renal measure
eGFR in mL/min/1.73 m2

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Severe renal impairment - eGFR 15 to below 30

IndicationOral regimen
Atopic dermatitis15 mg once daily
Ulcerative colitis30 mg once daily for 8-week induction, then 15 mg once daily maintenance
Crohn disease30 mg once daily for 12-week induction, then 15 mg once daily maintenance

Renal restrictions and indication scope

For these indications, ESRD with eGFR below 15 is not recommended. Mild or moderate impairment at eGFR 30 or higher does not require renal adjustment. Do not use this table to replace the rules for another indication or formulation.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Upadacitinib extended-release tablets (Rinvoq, selected adult indications) - selected U.S. label sections

Adult RINVOQ ER tablets for atopic dermatitis, ulcerative colitis or Crohn disease only. Not RINVOQ LQ, pediatric regimens, or other rheumatologic indications.

Renal method: eGFR in mL/min/1.73 m2
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Rinvoq

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected adult extended-release indication-specific renal guidance. Do not transfer to pediatric liquid dosing.

Renal method: eGFR, mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeUpadacitinib extended-release tablets (Rinvoq, selected adult indications) - selected U.S. label sectionsGlobalRPh RX List - Rinvoq
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095

Product and population scope

Adult RINVOQ ER tablets for atopic dermatitis, ulcerative colitis or Crohn disease only. Not RINVOQ LQ, pediatric regimens, or other rheumatologic indications.

RDM32-upadacitinib-rinvoq-er-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Upadacitinib extended-release tablets (Rinvoq, selected adult indications) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult RINVOQ ER tablets for atopic dermatitis, ulcerative colitis or Crohn disease only. Not RINVOQ LQ, pediatric regimens, or other rheumatologic indications.

Renal method: eGFR in mL/min/1.73 m2
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Severe renal impairment - eGFR 15 to below 30

IndicationOral regimen
Atopic dermatitis15 mg once daily
Ulcerative colitis30 mg once daily for 8-week induction, then 15 mg once daily maintenance
Crohn disease30 mg once daily for 12-week induction, then 15 mg once daily maintenance

RDM32-upadacitinib-rinvoq-er-1 · Source locator: 2, renal impairment dosage recommendations; 8.6

Renal restrictions and indication scope

For these indications, ESRD with eGFR below 15 is not recommended. Mild or moderate impairment at eGFR 30 or higher does not require renal adjustment. Do not use this table to replace the rules for another indication or formulation.

RDM32-upadacitinib-rinvoq-er-2 · Source locator: 2; 8.6

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095
Retrieved
2026-09-05
DailyMed Set ID
2966aec7-2ef0-923c-d8ff-fe1a957bf095
Renal-function method
eGFR in mL/min/1.73 m2
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
7d1df40c7abb8a96ea591f17701d0eda070720546e6248aa89e6e2248db1644a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Rinvoq

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Selected adult extended-release indication-specific renal guidance. Do not transfer to pediatric liquid dosing.

Renal method: eGFR, mL/min/1.73 m2.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For atopic dermatitis with eGFR 15 to less than 30 mL/min/1.73 m2, the recommended dose is 15 mg once daily. For ulcerative colitis or Crohn disease in that renal range, use 30 mg once daily for induction and 15 mg once daily for maintenance; indication-specific induction duration requires the complete label. Use for these indications is not recommended below eGFR 15. Adult rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis do not require renal dose adjustment for mild through severe impairment in this source.

RDM33-rxlist-upadacitinib-rinvoq-er-C1 · Source locator: Recommended dosage in renal impairment; use in specific populations.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/rinvoq-drug/
Retrieved
2026-09-07
Renal-function method
eGFR, mL/min/1.73 m2.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
e9df667a6814f2256a560cfd561f9c2c0969d572dbaa631b1673415818dde3da

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
1e645e073d7b160dddf5c13ee9aad760d45c5e31f2875748b7e3a82029c39a4e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report